AbbVie (ABBV) Revenue & Revenue Breakdown

AbbVie's yearly revenue for 2023 was $54.32B, representing a decrease of -6.44% compared to 2022. The company's yearly revenue for 2022 was $58.05B, representing an increase of 3.30% compared to 2021. ABBV's yearly revenue for 2021 was $56.2B, representing an increase of 22.69% compared to 2020.

AbbVie's quarterly revenue for Q2 2024 was $14.46B, a 17.48% increase from the previous quarter (Q1 2024), and a 4.31% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $12.31B, a -13.92% decrease from the previous quarter (Q4 2023), and a 0.70% increase year-over-year (Q1 2023). ABBV's quarterly revenue for Q4 2023 was $14.3B, a 2.69% increase from the previous quarter (Q3 2023), and a -5.42% decrease year-over-year (Q4 2022).

AbbVie's revenue growth rate for the last 3 years (2021-2023) was -3.34%, and for the last 5 years (2019-2023) was 63.28%.

AbbVie's revenue streams in c 23 are Other Neuroscience, Duodopa, Botox Therapeutic, Ubrelvy, Vraylar, Linzess/Constella, MAVYRET, Other Products, SKYRIZI, RINVOQ, H U M I R A, VENCLEXTA, Imbruvica, Restasis, Ozurdex, Other Eye Care, Lumigan/Ganfort, Alphagan/Combigan, Other Aesthetics, Juvederm Collection, Botox Cosmetic, and Qulipta. Other Neuroscience generated $276M in revenue, accounting 0.52% of the company's total revenue, down -41.89% year-over-year. Duodopa generated $468M in revenue, accounting 0.88% of the company's total revenue, up 2.18% year-over-year. Botox Therapeutic generated $2.99B in revenue, accounting 5.64% of the company's total revenue, up 10.00% year-over-year. Ubrelvy generated $815M in revenue, accounting 1.54% of the company's total revenue Vraylar generated $2.76B in revenue, accounting 5.20% of the company's total revenue, up 35.38% year-over-year. Linzess/Constella generated $1.11B in revenue, accounting 2.09% of the company's total revenue, up 7.05% year-over-year. MAVYRET generated $1.43B in revenue, accounting 2.70% of the company's total revenue, down -7.20% year-over-year. Other Products generated $3.04B in revenue, accounting 5.72% of the company's total revenue, down -26.64% year-over-year. SKYRIZI generated $7.76B in revenue, accounting 14.64% of the company's total revenue, up 50.30% year-over-year. RINVOQ generated $3.97B in revenue, accounting 7.49% of the company's total revenue, up 57.38% year-over-year. H U M I R A generated $14.4B in revenue, accounting 27.17% of the company's total revenue, down -32.17% year-over-year. VENCLEXTA generated $2.29B in revenue, accounting 4.32% of the company's total revenue, up 13.89% year-over-year. Imbruvica generated $3.6B in revenue, accounting 6.78% of the company's total revenue, down -21.28% year-over-year. Restasis generated $436M in revenue, accounting 0.82% of the company's total revenue, down -34.53% year-over-year. Ozurdex generated $472M in revenue, accounting 0.89% of the company's total revenue Other Eye Care generated $803M in revenue, accounting 1.51% of the company's total revenue, down -31.66% year-over-year. Lumigan/Ganfort generated $432M in revenue, accounting 0.81% of the company's total revenue, down -15.95% year-over-year. Alphagan/Combigan generated $272M in revenue, accounting 0.51% of the company's total revenue, down -21.39% year-over-year. Other Aesthetics generated $1.23B in revenue, accounting 2.33% of the company's total revenue, down -4.34% year-over-year. Juvederm Collection generated $1.38B in revenue, accounting 2.60% of the company's total revenue, down -3.50% year-over-year. Botox Cosmetic generated $2.68B in revenue, accounting 5.06% of the company's total revenue, up 2.56% year-over-year. Qulipta generated $408M in revenue, accounting 0.77% of the company's total revenue

For the fiscal year ending Dec 23, the largest source of revenue of AbbVie was H U M I R A. This segment made a revenue of $14.4B, representing 27.17% of the company's total revenue.